ArticleMicrobial cell factories2014
De novo production of the monoterpenoid geranic acid by metabolically engineered Pseudomonas putida.
Article in Microbial cell factories, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 83 citations in OpenAlex.
- Characterisation of metabolic burden in Pseudomonas putida reveals precursor limitation in heterologous lycopene production.Microbial cell factories · 2026Article
- Transcriptomic and Metabolomic Profiling of Heat Stress Responses and Ganoderic Acid Biosynthesis in Ganoderma lucidum.Applied biochemistry and biotechnology · 2026Article
- CRISPR/Cas9-Mediated Metabolic Engineering of EndophyticACS omega · 2026Article
- Strategic selection of microbial cell factories for sustainable and application-specific terpenoid production.Frontiers in bioengineering and biotechnology · 2026Review
- Biotransformation of Geraniol to Geranic Acid Using FungusACS omega · 2024Article
- Biosynthesis of geranate via isopentenol utilization pathway in Escherichia coli.Biotechnology and bioengineering · 2023Article
- Engineering isoprenoids production in metabolically versatile microbial host Pseudomonas putida.Biotechnology for biofuels and bioproducts · 2022Article
- A pBBR1-based vector with IncP group plasmid compatibility for Methylorubrum extorquens.MicrobiologyOpen · 2022Article
- Comparative metabolomic analysis of exudates of microcystin-producing and microcystin-freeFrontiers in microbiology · 2022Article
- Evaluation of P450 monooxygenase activity in lyophilized recombinant E. coli cells compared to resting cells.AMB Express · 2021Article
- Impact of culture condition modulation on the high-yield, high-specificity and cost-effective production of terpenoids from microbial sources: A review.Applied and environmental microbiology · 2021Review
- Diversifying Isoprenoid PlatformsFrontiers in microbiology · 2021Review
- Current Advances in the Bacterial Toolbox for the Biotechnological Production of Monoterpene-Based Aroma Compounds.Molecules (Basel, Switzerland) · 2020Review
- Industrial biotechnology of Pseudomonas putida: advances and prospects.Applied microbiology and biotechnology · 2020Review
- Investigation of monoterpenoid resistance mechanisms in Pseudomonas putida and their consequences for biotransformations.Applied microbiology and biotechnology · 2020Article
- Engineering Pseudomonas putida for isoprenoid production by manipulating endogenous and shunt pathways supplying precursors.Microbial cell factories · 2019Article
- Identifying and engineering the ideal microbial terpenoid production host.Applied microbiology and biotechnology · 2019Review
- Chasing bacterial chassis for metabolic engineering: a perspective review from classical to non-traditional microorganisms.Microbial biotechnology · 2019Review
- Rational Engineering of Phenylalanine Accumulation inFrontiers in bioengineering and biotechnology · 2019Article
- Discovery and engineering of an endophyticJournal of biological engineering · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProduction of monoterpenoids as valuable chemicals using recombinant microbes is a growing field of interest. Unfortunately, antimicrobial activity of most monoterpenoids hampers a wide application of microorganisms for their production. Strains of Pseudomonas putida, a fast growing and metabolically versatile bacterium, often show an outstanding high tolerance towards organic solvents and other toxic compounds. Therefore, Pseudomonas putida constitutes an attractive alternative host in comparison to conventionally used microorganisms. Here, metabolic engineering of solvent tolerant Pseudomonas putida as a novel microbial cell factory for de novo production of monoterpenoids is reported for the first time, exemplified by geranic acid production from glycerol as carbon source. The monoterpenoic acid is an attractive compound for application in the flavor, fragrance, cosmetics and agro industries.
resultsA comparison between Escherichia coli, Saccharomyces cerevisiae and Pseudomonas putida concerning the ability to grow in the presence of geranic acid revealed that the pseudomonad bears a superior resilience compared to the conventionally used microbes. Moreover, Pseudomonas putida DSM 12264 wildtype strain efficiently oxidized externally added geraniol to geranic acid with no further degradation. Omitting external dosage of geraniol but functionally expressing geraniol synthase (GES) from Ocimum basilicum, a first proof-of-concept for de novo biosynthesis of 1.35 mg/L geranic acid in P. putida DSM 12264 was achieved. Doubling the amount of glycerol resulted in twice the amount of product. Co-expression of the six genes of the mevalonate pathway from Myxococcus xanthus to establish flux from acetyl-CoA to the universal terpenoid precursor isopentenylpyrophosphate yielded 36 mg/L geranic acid in shake flask experiments. In the bioreactor, the recombinant strain produced 193 mg/L of geranic acid under fed-batch conditions within 48 h.
conclusionMetabolic engineering turned Pseudomonas putida DSM 12264, a versatile monoterpenoid oxidation biocatalyst, into an efficient microbial cell factory for de novo geranic acid production. Improvements by metabolic and process engineering are expected to further increase the product concentration. To the best of the authors' knowledge, this is the first example of a de novo production of a monoterpenoid with Pseudomonas putida and of a microbial monoterpenoic acid synthesis in general.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.